



## Press release

### STADA launches novel Parkinson's therapy in Germany and Austria

- In October, STADA acquired the rights to a triple combination product with the active ingredients levodopa, carbidopa and entacapone. This is now being launched in Germany and Austria for the treatment of advanced Parkinson's disease.
- STADA CEO Peter Goldschmidt: "With this new therapy option we are demonstrating that we are not only the go-to-partner for our Consumer Health and Generics businesses, but also for our strongly growing Specialty Pharmaceuticals segment."
- STADA Germany head Eelco Ockers: "We are delighted to be able to offer a novel triple-combination product with modern pump technology that strategically complements our neurology portfolio and continues our commitment to treating Parkinson's disease patients."

**Bad Vilbel, 15 February 2021** – STADA is launching a new triple combination product with modern pump technology for the treatment of advanced Parkinson's disease in Germany and Austria. Other European markets will follow. In Germany, this prescription therapy will be launched with immediate effect by STADAPHARM GmbH, which is responsible for the Specialty Pharmaceuticals business in the STADA Group and brings extensive experience with apomorphine injection and infusion treatments for Parkinson's disease. The novel gel formulation of the three established Parkinson's active ingredients levodopa, carbidopa and entacapone has a positive effect on the bioavailability of levodopa in the body.<sup>1</sup> This is administered via the small intestine using modern pump technology. The pump can be removed and patients can even bathe, shower or swim – if their overall condition permits. This offers patients the chance to plan and master their daily lives and is an excellent

---

<sup>1</sup> Senek M, et al. *Mov Disord.* 2017;32(2):283-6



example of how STADA is increasingly offering added value for patients and caregivers with differentiated specialty pharmaceuticals. From a company perspective, these products have, due to their differentiation, the potential for sustainable margins over many years.

"We care about people's health and are now also fulfilling this mission with a new therapy option for treating Parkinson's disease," emphasises STADA CEO Peter Goldschmidt. "With this, we are demonstrating that we are not only the go-to-partner for our Consumer Health and Generics businesses, but also for our strongly growing Specialty Pharmaceuticals segment."

STADA's Head of Germany, Eelco Ockers, adds: "We are very pleased to be the first company in Germany to offer a novel triple combination product with a modern pump technology that makes a valuable contribution to caring for Parkinson's patients. The gel formulation is a strategically important addition to our portfolio through which we are intensifying our commitment in the field of neurology and benefiting from our previous experience."

The new therapy option is an infusion therapy administered through a modern, discreet, lightweight and portable pump via a tube into the small intestine. The pump has an intuitive and user-friendly interface and a long battery life. Healthcare professionals can programme multiple flow rates to suit different patient needs.

To accompany the launch, STADAPHARM is offering a specialist patient service that supports patients and their relatives in clinics and at home during therapy. In addition, a 24-hour hotline provides technical support for pump-related questions, while a complete package of support materials has been compiled for patients and their doctors.



**About STADA Arzneimittel AG**

STADA Arzneimittel AG is headquartered in Bad Vilbel, Germany. The company focuses on a two-pillar strategy consisting of generics, including specialty pharmaceuticals and non-prescription consumer health products. Worldwide, STADA Arzneimittel AG sells its products in approximately 120 countries. In financial year 2019, STADA achieved adjusted Group sales of EUR 2,608.6 million and adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of EUR 625.5 million. As of December 31, 2019, STADA employed 11,100 people worldwide.

***Additional information for journalists:***

STADA Arzneimittel AG  
Media Relations  
Stadastrasse 2-18  
61118 Bad Vilbel - Germany  
Phone: +49 (0) 6101 603-165  
Fax: +49 (0) 6101 603-215  
E-Mail: [press@stada.de](mailto:press@stada.de)  
Or visit us on the Internet at [www.stada.com/press](http://www.stada.com/press)

***Additional information for capital market participants:***

STADA Arzneimittel AG  
Investor & Creditor Relations  
Stadastrasse 2-18  
61118 Bad Vilbel – Germany  
Phone: +49 (0) 6101 603-4689  
Fax: +49 (0) 6101 603-215  
E-mail: [ir@stada.de](mailto:ir@stada.de)  
Or visit us on the Internet at [www.stada.com/investor-relations](http://www.stada.com/investor-relations)

Executive Board: Peter Goldschmidt (CEO) / Dr. Wolfgang Ollig / Miguel Pagan Fernandez  
Supervisory Board Chairman: Dr. Günter von Au